re: off-label market size
Forgive me if I misunderstood something, and I guess it all depends on the definition of the word 'significant', but I am working with an intensive care database of 4000 patients from 14 university- hospital intensive care units all over Germany, which I think is the biggest drugs market in Europe. Out of curiosity, I had a look at patients who received antithrombin: 30.
Unfortunately the way the ICD diagnosis code and description is entered into that database does not allow me to say for all patients for sure who had hereditary and who had acquired a. deficiency, but given that these are university hospital ICUs and most are really sick patients, I would hazard a guess that most of these are acquired a. deficiency.
I do not know the state of supply with plasma-derived a. in Germany and I suppose another factor is the price of Atryn relative to its competitors (because hospital care is reimbursed on a per-case DRG system in Germany), but based on my data and my limited understanding of the issue, I would assume though that relative to the market size for the HD indication, the off-label market for Atryn in hospitals in Germany at least may not be insignificant.
Please correct my thinking if I am missing something.
Market Data 
Markets 
AI
